Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients
Related Articles
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
Objective To assess safety outcomes for the induction therapies alemtuzumab and autologous hematopoietic stem cell transplantation (AHSCT) compared to noninduction disease-modifying therapies. Methods We performed…
Editors' Note: Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults
Dr. Xu et al. analyzed the association of kidney function with the risk of dementia in a registry of 329,822 residents of Stockholm (2006–2011), additionally…
Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy
Objective To determine whether the punctuated administration of low-dose rituximab, temporally linked to B-cell hyperrepopulation (defined when the return of CD19+ B cells approximates 40%–50%…
Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults: A Registry-Based Study
Objective Community-based reports regarding the association between the estimated glomerular filtration rate (eGFR) and dementia risk show conflicting results. The aim of this study is…
Precision Intravenous Immunoglobulin Dosing and Clinical Outcomes: A Retrospective Chart Review
Objectives: Intravenous immunoglobulin (IVIg) is used for treatment of acute neurologic conditions such as Guillain–Barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy relapse, and myasthenia gravis exacerbation.…
English
العربية
简体中文
Nederlands
Français
Deutsch
Italiano
Português
Русский
Español
Responses